Gastro-protective treatment in patients using NSAIDs: Development of appropriateness criteria by a multidisciplinary expert panel

Scandinavian Journal of Rheumatology

Volumn 32, Issue 3, 2003, Pages 162-167

  Stoevelaar, H J ^a   McDonnell, J ^a   Stals, H ^b   Smets, L ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ISMAR Healthcare ^*  (Belgium)

Author keywords

Adverse events; Expert opinion; Gastro protective medication; Gastrointestinal complications; Non steroidal anti inflammatory drugs; RAND method

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GASTROPROTECTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PEPTIC ULCER; PRIORITY JOURNAL; RAND APPROPRIATENESS METHOD; RATING SCALE; SCORING SYSTEM; TREATMENT INDICATION; VALIDATION PROCESS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; DECISION SUPPORT TECHNIQUES; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATION; PATIENT CARE PLANNING; PROTECTIVE AGENTS; REGRESSION ANALYSIS;

EID: 0038683614     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740310002506     Document Type: Article

References (27)

1. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2037-46.
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99.
3. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-9.
4. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software.
5. Koch M, Dezi A, Ferrario F, Capurso L. Prevention of nonsteroidal anti-inflammatory drug-induced mucosal injury. A meta-analysis of randomised controlled clinical trials. Arch Intern Med 1996;156:2321-32.
6. Goldstein JL. Who needs prophylaxis of nonsteroidal anti-inflammatory drug-induced ulcers and what is optimal prophylaxis? Eur J Gastroenterol Hepatol 2000;12 Suppl:S11-5.
7. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
8. Elliott SL, Yeomans ND, Buchanan RR, Smallwood RA. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial. Scand J Rheumatol 1994;23:171-6.
9. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swanell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:727-34.
10. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, Van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:719-26.
11. Yeomans N, Wilson I, Langstrom G, Hawkey C, Naesdal J, Walan A, et al. Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoproestol. Scand J Rheumatol 2001;30:328-34.
12. Taha AS, Dahill S, Sturrock RD, Lee FD, Russell RI. Predicting NSAID related ulcers. Assessment of clinical and pathological risk factors and importance of differences in NSAID. Gut 1994;35:891-5.
13. Scarpignato C, Bjarnason I, Bretagne JF, De Pouvourville G, Garcia Rodriguez LA, Goldstein JL, et al. Towards a GI safer anti-inflammatory therapy. Gastroenterol Int 1999;12:186-215.
14. McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med 1998;105:3S-9S.
15. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: Regression analysis of the MUCOSA trial. Fam Med 1996;28:204-10.
16. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40.
17. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
18. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
19. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530-6.
20. Hawkey CJ. What consideration should be given to Helicobacter pylori in treating nonsteroidal anti-inflammatory drug ulcers? Eur J Gastroenterol Hepatol 2000;12 Suppl 19:S17-20.
21. Henry D, Lim LLY, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
22. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: a cohort study. BMJ 1997;315:1333-7.
23. Ekström P, Carling L, Wetterhus S, Wingren PE, Anker-Hansen O, Lundegardh G, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996;31:753-8.
24. Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998;12:135-40.
25. Kahn KL, Kosecoff J, Chassin MR, Flynn MF, Fink A, Pattaphongse N, et al. Measuring the clinical appropriateness of the use of a procedure. Can we do it? Med Care 1988;26:415-22.
26. Brook RH, Chassin MR, Fink A, Solomon DH, Kosecoff J, Park RE. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986;2:53-63.
27. Black N, Murphy M, Lamping D, McKee M, Sanderson C, Askham J, et al. Consensus development methods: a review of best practice in creating clinical guidelines. J Health Serv Res Policy 1999;4:236-48.